Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decitabine limits escape from MEK inhibition in uveal melanoma

23 Nov 2019

Abstract excerpt

MEK inhibitors (MEKi) demonstrate anti-proliferative activity in patients with metastatic uveal melanoma, but responses are short-lived. In the present study, we evaluated the MEKi trametinib alone and in combination with drugs targeting epigenetic regulators, including DOT1L, EZH2, LSD1, DNA methyltransferases, and histone acetyltransferases. The DNA methyltransferase inhibitor (DNMTi) decitabine effectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ocular Oncology and Treatments
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31758842
DOI: 10.1111/pcmr.12849

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decitabine limits escape from MEK inhibition in uveal melanomaPMID 31758842Read ↗

Identification of targetable epigenetic vulnerabilities for uveal melanomaSemantic proximity Read ↗

Targeting Epigenetic Modifications in Uveal MelanomaSemantic proximity Read ↗

Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell linesSemantic proximity Read ↗

AURKB Enhances Chromosomal Remodeling of Telomeric Genes and Accelerates Tumorigenesis of Uveal MelanomaSemantic proximity Read ↗

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.Semantic proximity Read ↗

Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanomaSemantic proximity Read ↗

Development of new therapeutic options for the treatment of uveal melanomaSemantic proximity Read ↗

Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal MelanomaSemantic proximity Read ↗

Azacytidine Treatment Affects Methylation Pattern of Genomic and Cell-Free DNA in Uveal Melanoma Cell LinesSemantic proximity Read ↗

Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal MelanomaSemantic proximity Read ↗

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant MelanomasSemantic proximity Read ↗

An overview of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.